palmitoylethanolamide.com.au
HomeResearchArdizzone 2021

Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain

Ardizzone A, Fusco R, Casili G, Lanza M, Impellizzeri D, Esposito E, Cuzzocrea S. International Journal of Molecular Sciences, 2021; 22(4):1967.

Laboratory studyOther animalsWith acetyl-L-carnitine

This study tested palmitoylethanolamide together with acetyl-L-carnitine. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Laboratory study
Subjects
Male laboratory rats, 10 per group, with paw inflammation caused by carrageenan
Dose used in the study
Ultramicronised palmitoylethanolamide at 2.5 or 5 mg/kg, acetyl-L-carnitine at 2.5 or 100 mg/kg, plain palmitoylethanolamide at 100 mg/kg, and combinations, all by mouth 30 minutes before the injection
Duration
6 hours
What was measured
Paw swelling, heat sensitivity, inflammatory cells, mast cells and inflammatory proteins in the paw

What the authors reported

The authors reported that the combined product at 5 mg/kg reduced swelling, heat sensitivity, mast cell infiltration and inflammatory markers, and did so more than either compound alone at higher doses, and more than a 200 mg/kg plain mixture.

Limits of this study

A single acute rat model over 6 hours, which the authors name as a limit. The study was funded by Epitech Group, which supplied the compounds, and the senior author is a co-inventor on Epitech patents covering them.

Source

doi:10.3390/ijms22041967

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.